Is there a future for other glutamate receptor modulators in the pharmacotherapy of mood disorders?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F16%3A43915270" target="_blank" >RIV/00023752:_____/16:43915270 - isvavai.cz</a>

Result on the web

<a href="http://ebmh.bmj.com/content/19/3/95.full" target="_blank" >http://ebmh.bmj.com/content/19/3/95.full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1136/eb-2015-102261" target="_blank" >10.1136/eb-2015-102261</a>

Result language

angličtina

Original language name

Is there a future for other glutamate receptor modulators in the pharmacotherapy of mood disorders?

Original language description

There is increasing evidence that some glutamatergic drugs could have antidepressant effects. Ketamine as a promising prototype for novel glutamatergic antidepressants has a much faster onset of action and is possibly more efficacious than standard antidepressants. The author comments the results of two recent systematic reviews and meta-analyses assessed the antidepressant efficacy (including modes of administration, duration of effect and adverse effects) of ketamine and other glutamate receptor modulators in the treatment of unipolar depression (Caddy et al. 2015 in the Cochrane Database of Systematic Reviews), and, more generally, in mood disorders (Newport et al. 2015 in the American Journal of Psychiatry). In line with findings of previous reviews examining the efficacy of only ketamine, both of the reviews commented on here demonstrated that a single application of a sub-anaesthetic dose of ketamine reliably produces a rapid anti-depressant effect lasting up to 1 week. No evidence was found for the antidepressant efficacy of the other glutamate receptor modulators, even though NMDA partial agonists for the glycine site, D-cycloserine and rapastinel/GLYX-13, had positive effects on mood without causing dissociation. Interestingly, ketamine is also distinguished from the other NMDA antagonists by the frequency of its psychotomimetic and dissociative effects. The vast majority of the studies in these reviews included small sample sizes. Forthcoming ketamine research should continue to examine three central concerns: (1) elucidating ketamine's mechanism of action including the specificity of effect to NMDA antagonism; (2) understanding the administration profile necessary to provide a sustained therapeutic benefit with optimised non-parenteral administration and (3) examining ketamine's long-term safety profile, particularly with repeated and low-dose administration.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

AN - Psychology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Evidence - Based Mental Health: an international digest for mental health clinicians

ISSN

1362-0347

e-ISSN

—

Volume of the periodical

19

Issue of the periodical within the volume

3

Country of publishing house

US - UNITED STATES

Number of pages

2

Pages from-to

95-96

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-84973355622